lorlatinib will decrease the level or result of ergotamine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Keep away from or Use Alternate Drug. Avoid usage of lorlatinib with CYP3A substrates, where by minimal concentration changes may possibly lead to really serious therapeutic failures